Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AboveFinancial, additonal, AGMp, allo, Ana, andwaste, Antonio, apparent, appellate, ASCVD, aspart, autoinflammatory, azido, backdrop, banned, BELINDA, Benz, Bergen, bevacizumab, Bladder, BSE, BuechnerB, BulaB, businessp, cacy, Cameroon, candidatesBased, card, Catalyst, cation, ceased, cephalosporin, CGU, chose, cific, Claudia, COI, col, commercializationi, CommitteeSCIENCE, CommitteeT, competitivenessp, Concurrently, consumptione, contraindicated, cor, County, cure, curing, dampened, dangerously, Dayp, dengue, deputy, dermal, developmentsp, Diabetology, disabilityAccelerated, disagreement, disappointing, disclaimer, dMeetingsNumber, EDM, effi, eMeetingsNumber, enjoin, ensovibep, epi, erwise, esophageal, excused, feel, flu, foregoing, formulaStep, Fortum, forwardi, glance, glargine, Gonzalo, graphical, groupAbbvieBiogenGlaxoSmithKlineNovo, groupp, growthp, Gyroscope, Hale, HaleChief, harder, HARMONIA, heat, HeFH, hemolytic, Hepatocellular, HiSCR, HRSA, HS, humidity, hypothetical, IBOR, ID, illustrate, illustration, implementationPatient, impurity, incidenti, incon, indica, Indonesia, infor, inline, inorganic, Interbank, intrinsic, jeopardize, JPsA, Karen, KowalskiChief, landlord, libvatrep, LID, linear, lispro, log, login, longest, LVEF, map, marketsp, mation, mattersp, MAXIMISE, Maze, MetETHICAL, MetStrategic, millionMetGroup, monitoringof, morbidity, MRI, multicounty, mutagen, NaN, Nasopharyngeal, NBIM, NHS, NICE, Nigeria, NordiskRocheAmgen, Nurse, ociperlimab, Officep, OfficerHarry, OIG, Omicron, orderly, oth, oversightDesign, Pakistan, palbociclib, password, PayoutOverall, PAYOUTPayoutThe, performanceAll, performanceAnnual, performanceUnvested, PFS, Pharmacia, placei, PLANAward, poorest, porate, port, Prime, programsi, protease, PSUsGlobal, QR, quent, quiet, rangeFinancial, rash, Rawlinson, redesign, RegulationsExecutive, rem, remanded, replication, resultse, revisit, Rob, RSUsRetirement, Rwanda, RWE, Sandozi, sBLA, scarcity, Scemblix, SDOE, setsProvide, settingFinancial, sincerest, sistent, SLB, softer, spe, stay, stretch, Subse, Subtotal, sugar, SUNRISE, SUNSHINE, surpassed, swelling, switching, Symposium, synergistic, targetNet, targetse, targetThreshold, targetTSR, teamwork, terminology, tetraxetan, throughput, TIGIT, topline, TPRM, transcription, treasurer, trendsp, TSRTarget, UCB, unaffected, undermine, uremic, urothelial, utmost, vacated, valuee, vehiclePerformance, Vicki, vide, vipivotide, wake, weak, workplace, XBRL, yearslong, Zinacef, Zinnat
Removed:
adalimumab, Advair, Afinitor, agreementAll, ALS, Amazon, amyotrophic, angiomyolipoma, antibacterial, anticompetitive, antiviral, ARB, asciminib, asserting, assetsTaxesCapital, assuming, astrocytoma, BaertChief, Bahrain, Belgian, Berkeley, biggest, bind, blocker, brain, Brentford, Britain, bromide, capmatinib, Carnegie, Carolina, centralize, CFTR, chairmanship, Chapel, CHFAnnual, companion, compelling, computation, congressional, conjugation, considerable, Conversely, COPD, CRL, cultural, currenciesThe, cyclepayout, Daimler, DatarA, DatarE, deactivate, declared, Delta, derecognized, desire, deviation, discontinuation, discontinue, discouraging, dismutase, dispersible, Disperz, donation, driver, drove, dysfunction, EMI, enabled, enoxaparin, etanercept, evolution, exemestane, extracted, fevipiprant, fluticasone, formed, genetically, Georgia, giant, hcl, Heineken, hereinafter, Hill, Hudson, hydrochlorothiazide, ICF, immigration, inconsistent, indacaterol, indemnify, inhaled, insight, instability, instruct, interval, intervention, intrathecal, investmentsExecutive, journey, KPIT, lactam, Lafarge, leave, legacy, Les, liver, Lotrel, Luc, mCRPC, Middlesex, misconductAll, Momenta, mometasone, mTOR, Music, neurological, nil, nominating, nuclear, observing, obstructive, OfficerShannon, OfficerSteven, onward, ordering, organ, outcomefor, outperform, Outperformance, pace, Paul, PAYOUTPayoutOverall, pembrolizumab, performanceAward, PLANSGrant, PlantaC, PlantaE, potentiator, preliminary, promotional, propionate, PSUsTarget, pulmonary, reasonNo, reinforcing, reorganize, Rett, rheumatoid, RSUsIf, RTT, salaryLTRPP, salaryPayout, salmeterol, scheme, SEGA, segregation, sharply, Sherpany, shift, shifted, simplification, Solvay, space, spartalizumab, speed, Stanford, Starlix, statistically, STOXX, Stryker, subependymal, sublicensed, succeed, superoxide, supplanted, swing, Tabular, tendered, Tennessee, tisagenlecleucel, TNF, tool, transplantation, triple, Trump, TSC, turned, undone, unfair, uniform, unresolved, USAN, validly, Valturna, var, vector, Votubia, WACC, wave, worsened, worth, yearsEquity, yield
Filing tables
Filing exhibits
Associated NVS transcripts
NVS similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-171739, 333-198706, 333-250207 and 333-258081) and Form F-3 (No. 333-236162) of Novartis AG of our report dated February 1, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F.
/s/ PricewaterhouseCoopers AG
Basel, Switzerland
February 1, 2022